Welcome to our dedicated page for Assembly Bioscie news (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Bioscie stock.
Assembly Biosciences, Inc. reports developments for a clinical-stage biotechnology business focused on small-molecule therapeutics for serious viral diseases. Its recurring updates center on investigational antiviral candidates for herpes simplex virus, hepatitis delta virus and hepatitis B virus, including helicase-primase inhibitors ABI-5366 and ABI-1179, the HDV entry inhibitor ABI-6250 and the HBV capsid assembly modulator ABI-4334.
Company news also covers clinical data presentations, financial results, research and collaboration revenue, the Gilead collaboration and licensing activity, and equity financing transactions that support pipeline development.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Assembly Biosciences (Nasdaq: ASMB) has shared Phase 1a clinical data for its HBV core inhibitor, ABI-4334, which shows promising efficacy against viral replication and cccDNA formation. The company is actively considering partnering options for its core inhibitor portfolio, aiming to advance the development of these therapies. In addition, Assembly Bio is prioritizing its antiviral pipeline, including ABI-5366 for high-recurrence genital herpes, with plans to enter clinical trials in the first half of 2024. The financial outlook remains strong, with an estimated cash runway extending into Q3 2024. CEO Jason Okazaki highlighted the need for longer-duration studies to validate the efficacy of core inhibitors. Overall, the results suggest a strong foundation for future development in HBV treatments.